One mefunidone-treated subject (11.1%) in the B2 cohort and one mefunidone-treated subject (11.1%) in the B3 cohort had six TEAEs of moderate degree (hypertriglyceridemia, alanine aminotransferase increase, and dizziness in the B2 cohort and tonsillitis, hyponatremia, and alanine aminotransferase increase in the B3 cohort). This evidence concerns the gene GPT and medical procedure.